AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

RecruitingNAAges 18 Years - 85 YearsAllIRCCS Centro San Giovanni di Dio Fatebenefratelli
💬

In plain words

What the trial is, and whether it could suit you

The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD) patients, as compared to the general population. These disorders result in an impairment of the individual's abilities to perform daily tasks. As their disease progresses, patients become dependent on medical services and on family support. Given the limited effectiveness of pharmacological treatments, non-pharmacological interventions to prevent and treat cognitive deficits and the associated difficulties with activities of daily living in neurodegenerative disease patients have gained attenti

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints); * Montreal Cognitive Assessment (MoCA) corrected score ≥17.36 * Education ≥ 5 years * Age eligible for the study: 18≤age≤85 * Native Italian speakers * Absence of marked hearing/visual impairment * All of the subjects will have normal or corrected-to-normal vision. * Agreement to participate by signing the informed consent form * Availability of a caregiver/study partner able to support the participant * No rehabilitation program in place at the time of enrolment or in the last 3 months before enrolment * Stable drug treatment (last 3 months), if any Exclusion Criteria: * Presence of any medical or psychiatric illness that could interfere with completing assessments; * Presence of any medical condition representing a contraindication to TMS.
💊

What it tests

  • RICORDO-DTx
  • Home-based unstructured cognitive stimulation
📍

Where

3 sites
IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
Brescia, Italy
IRCCS Centro Neurolesi Bonino Pulejo
Messina, Italy
Fondazione Don Carlo Gnocchi - ONLUS, Milan
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy